Wyeth at outperform by Bear Stearns

Bear Stearns analyst John Boris reiterated Wyeth at outperform. The analyst increased earnings-per-share estimates for 2007 to 2009 to $3.50, $3.88 and $4.27, from $3.45, $3.78 and $4.17 and the year-end price target to $57 from $55. Wyeth's Prevnar is approved in 77 countries and launched in 58, but there are only national reimbursement programs in 12. The Prevnar vaccine market model assumes less than 25% penetration or about $4 billion. Shares of the Madison, N.J., pharmaceutical company were down 30 cents, or 0.59%, at $50.59. (NYSE: WYE)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.